Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 10/20 | 0.53 |
| ▸ | MC4R | P32245 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786983 | 1.00 | KISS1R (0.53) | KISS1RMC4RACE | |
| SCHEMBL31184496 | 1.00 | KISS1R (0.53) | KISS1RMC4RACE | |
| SCHEMBL29476104 | 1.00 | KISS1R (0.53) | KISS1RMC4RACE | |
| SCHEMBL29511055 | 1.00 | KISS1R (0.53) | KISS1RMC4RACE | |
| SCHEMBL30276243 | 0.97 | MC4R (0.53) | KISS1RMC4RACE | |
| SCHEMBL29511018 | 0.96 | KISS1R (0.58) | KISS1RACE | |
| SCHEMBL29511037 | 0.96 | KISS1R (0.58) | KISS1RACE | |
| SCHEMBL30166970 | 0.95 | MC4R (0.56) | KISS1RMC4R | |
| SCHEMBL31249518 | 0.95 | MC4R (0.55) | KISS1RMC4R | |
| SCHEMBL31249537 | 0.95 | MC4R (0.55) | KISS1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| CN-118271400-A | Peptide composition | 节奏制药公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118240012-A | Peptide composition | 节奏制药公司 | 2024-06-25 | — | — | CN | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | KISS1R 2149/4885MC4R 268/4885ACE 3942/4885 |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | KISS1R 75/4885MC4R 1/4885ACE 2940/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | KISS1R 417/4885MC4R 8/4885ACE 3407/4885 |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | KISS1R 170/4885MC4R 1/4885ACE 1387/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | KISS1R 155/4885MC4R 1/4885ACE 1785/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | KISS1R 232/4885MC4R 4/4885ACE 3249/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | KISS1R 2023/4885MC4R 585/4885ACE 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.